Close Menu

Myriad Genetics won a significant victory last month when an appeals court upheld the company's gene patents. But now, The New York Times' Andrew Pollack says, the real battle starts for Myriad. Some experts say the company's test for the BRCA1 and BRCA2 mutations is "technologically outmoded, incomplete and too costly," Pollack reports.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.